Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026

Insmed announced on July 16 positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term safety, tolerability, and effectiveness of […]

Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026

A French multicenter trial (9 centers, 2015–2022) tested whether a 3-month supervised rehabilitation program improves 12-month exercise capacity in pulmonary arterial hypertension patients, using a Zelen design to limit performance bias — addressing a gap left by prior short-term, open-label studies. Key findings: Conclusion: A 3-month supervised rehabilitation program produced a durable, significant improvement in

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026 Read Post »

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor

Beyond hemodynamics and treatment targets, there are conversations with patients that rarely make it into clinical guidelines — yet they’re often the ones that matter most. That’s the message from Susanne McDevitt, DNP, a critical care nurse practitioner with the Pulmonary Hypertension (PH) Program at Michigan Medicine, University of Michigan, Ann Arbor. In a conversation

Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor Read Post »

Quality of Life Outcomes in Patients with Pulmonary Hypertension Receiving Prostacyclin Therapy: Impact of Anxiety, Depression, Sociodemographic Characteristics, and Treatment-Related Factors, Turkish Cardiology Journal, July 6, 2026

A cross-sectional study conducted between July 2023 and September 2024 examined factors affecting quality of life (QoL) in 58 pulmonary arterial hypertension patients on prostacyclin therapy, using validated scales (PAHSS for symptoms, HADS for anxiety/depression, EmPHasis-10 for quality of life). Key findings: Conclusion: Despite prostacyclin therapy, quality of life remains significantly compromised in patients —

Quality of Life Outcomes in Patients with Pulmonary Hypertension Receiving Prostacyclin Therapy: Impact of Anxiety, Depression, Sociodemographic Characteristics, and Treatment-Related Factors, Turkish Cardiology Journal, July 6, 2026 Read Post »

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026

A review recently published in Pulmonary Circulation brings together academic and industry researchers (via the PVRI Innovative Drug Discovery Initiative) to consolidate current knowledge on activin signaling inhibitors (ASIs), the role of specific Bone morphogenetic protein (BMP) ligands, efficacy/safety data, and considerations for developing next-generation activin signaling inhibitors. Key points: Open questions remain about: the

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026 Read Post »

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026

In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic barriers and discrimination—not biological differences.

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026 Read Post »

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026

A recent article by Dr. Iain Armstrong and Peter Winter examines a critical blind spot in digital health ethics known as “misrecognition”, which occurs when artificial intelligence systems evaluate patients solely through easily quantifiable metrics. By prioritizing standardized data over the complex, subjective realities of living with a chronic illness, AI tools inadvertently foster epistemic

The Ethical Application of Artificial Intelligence in Digital Health, European Heart Journal – Digital Health, Volume 7, Issue 6, July 2026 Read Post »

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): findings from the phase 3 study, The Lancet, July 26, 2026

ADVANCE OUTCOMES is a phase 3, randomised, double-blind trial tested oral ralinepag against placebo in pulmonary arterial hypertension patients, measuring time to first clinical worsening (death, hospitalisation, need for parenteral/inhaled prostacyclin therapy, disease progression, or unsatisfactory clinical response). Patients were enrolled between Jan 24, 2019, and June 20, 2025. Of 1037 patients screened for eligibility,

Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): findings from the phase 3 study, The Lancet, July 26, 2026 Read Post »

U.S. Food and Drug Administration (FDA) grants orphan drug status to IKT-001, an experimental formulation of imatinib to treat pulmonary arterial hypertension, July 23, 2026

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to IKT-001, an experimental formulation of imatinib that Inhibikase Therapeutics is developing to treat pulmonary arterial hypertension (PAH). Orphan drug designation is granted to investigational medications aimed at treating rare diseases — conditions affecting fewer than 200,000 people in the U.S. The designation is meant to give

U.S. Food and Drug Administration (FDA) grants orphan drug status to IKT-001, an experimental formulation of imatinib to treat pulmonary arterial hypertension, July 23, 2026 Read Post »

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026

In a single-centre Japanese cohort of 101 patients with haemodynamically severe pulmonary arterial hypertension treated with parenteral prostacyclin (1999–2023), 22 patients (22%) achieved near-normal haemodynamics and were successfully weaned off prostacyclin, all without adverse events, after a mean of 7.7 years of treatment. Those who de-escalated tended to have started prostacyclin earlier in their disease

Study finds that early parenteral prostacyclin therapy enables near-normal haemodynamics in severe pulmonary arterial hypertension patients, European Respiratory Journal, July 16, 2026 Read Post »

Respiratory inhaler devices market positioned for notable expansion through 2030, Open PR, July 13, 2027

An article recently published in Open PR notes that inhaler devices are seeing broadening use for managing several respiratory conditions, with pulmonary arterial hypertension listed alongside asthma and COPD as one of the areas of application. The report is about the respiratory inhaler devices market overall — smart/connected inhalers, market size projections (forecast to reach

Respiratory inhaler devices market positioned for notable expansion through 2030, Open PR, July 13, 2027 Read Post »

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026

Over the past 40 years, treatment for pulmonary arterial hypertension (PAH) has changed dramatically. What was once considered a disease with very few treatment options is now managed with a growing range of therapies that help people live longer and enjoy a better quality of life. A review recently published in Circulation looks back at

Pulmonary Arterial Hypertension: How far we’ve come—and what’s next, Circulation, July 13, 2026 Read Post »

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026

Natalia Maeva, a patient advocate for pulmonary hypertension, attended the European Respiratory Society (ERS) Presidential Summit in Warsaw in June 2026, participating in sessions on early detection, air quality, tobacco control, climate change and lung health. Having had her own life transformed by access to specialised treatment and lung transplantation, she found the discussions on

Patient advocate Natalia Maeva at the European Respiratory Society (ERS) Presidential Summit, Warsaw 2026 Read Post »

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026

Researchers at the Suqian First Hospital in Suqian, Chian, China tested whether adding mindfulness-based stress reduction (MBSR) to standard cardiopulmonary rehabilitation could benefit pulmonary arterial hypertension patients more than usual care alone. Fifty stable patients were split into two groups: one did a 6-week combined mindfulness-based stress reduction and rehab program, the other received standard

Study finds combining mindfulness with rehab exercise improves cardiopulmonary performance and psychological stress in pulmonary arterial hypertension patients, Canadian Respiratory Journal, June 29, 2026 Read Post »

Flolan discontinuation confirmed in the UK as of April 2028 – 150 patients in the UK will need to transition to another formulation of epoprostenol, PHA UK News, June 17, 2026

GSK has confirmed it will discontinue Flolan, a drug used to treat pulmonary arterial hypertension, in the UK from 2028 — having already pulled it from the US (see our article on this topic here), and other markets. Around 150 UK patients, including children, currently rely on the drug. With production ending in April 2028

Flolan discontinuation confirmed in the UK as of April 2028 – 150 patients in the UK will need to transition to another formulation of epoprostenol, PHA UK News, June 17, 2026 Read Post »

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026

A US web-based survey involving 200 respondents across 42 states was completed Sept–Oct 2023. The survey explored how patients with pulmonary arterial hypertension (PAH) understand and experience palliative care — which can be offered alongside standard treatment to ease symptoms and improve quality of life, but is underused and often misunderstood. Most respondents equated palliative

Web-based survey explores patient perspectives on palliative care in pulmonary arterial hypertension in the US, Pulmonary Circulation, June 24, 2026 Read Post »

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026

This “How I Do It” article addresses a practical question now facing pulmonary arterial hypertension (PAH) clinicians: as sotatercept gets added to background combination treatment, some patients on prostacyclin therapy show sustained improvement — raising the question of whether their prostacyclin dose can be safely reduced. The challenge is that standard monitoring tools (functional class,

How I Do It: De-escalation of Prostacyclin-Based Therapy in Patients Treated With Sotatercept, Chest Journal, June 24, 2026 Read Post »

Do financial conflicts of interest influence medical prescribing practices? A Yale study published in Medical XPress, June 16, 2026

A Yale study, published in Pulmonary Circulation, examined links between pharmaceutical industry payments and prescribing patterns among physicians treating pulmonary arterial hypertension (PAH) — a field chosen because therapies are costly and prescribing is concentrated among a small group of specialists. Using CMS Open Payments data, researchers found that physicians receiving drug-specific industry payments were

Do financial conflicts of interest influence medical prescribing practices? A Yale study published in Medical XPress, June 16, 2026 Read Post »

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition

Bronchiolitis obliterans syndrome (BOS) is the most common form of chronic lung allograft dysfunction after lung transplant, marked by progressive small airway disease with limited treatment options. This case report describes a 55-year-old woman with primary ciliary dyskinesia, post-bilateral lung transplant, who developed severe (stage 3) bronchiolitis obliterans syndrome and went into respiratory failure requiring

Could sotatercept treatment be effective in patients with end-stage bronchiolitis obliterans syndrome after lung transplantation? Journal of Heart and Lung Transplant, August 2026 edition Read Post »

Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives prestigious 2026 Rino Aldrighetti Leadership Award by the Pulmonary Hypertension Association (PHA) – June 18, 2026

The Rino Aldrighetti Leadership Award is the highest honor presented by the Pulmonary Hypertension Association (PHA). The award honors people who have shown outstanding leadership, commitment, and worldwide influence in raising PH awareness, supporting patients, and pushing forward treatment options. Omitogun was diagnosed with pulmonary hypertension in 2013 after a congenital heart defect, and over

Ayotunde Omitogun, founder of the Cardiac Community in Nigeria, receives prestigious 2026 Rino Aldrighetti Leadership Award by the Pulmonary Hypertension Association (PHA) – June 18, 2026 Read Post »

TRANSLATE »
Scroll to Top